{"id":356005,"date":"2026-11-19T16:15:10","date_gmt":"2026-11-19T10:45:10","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=356005"},"modified":"2026-11-19T16:15:10","modified_gmt":"2026-11-19T10:45:10","slug":"amanta-healthcare-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/","title":{"rendered":"Amanta Healthcare Analyst Review 2027: Profit Up Fourfold as the Stock Nears Its High"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Amanta Healthcare Stock Snapshot (19 Nov 2026)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b9239.15<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9245.70 \/ \u20b992.00<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b9928 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 50.7 vs 51.5<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b983.13 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b94.86 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Amanta Healthcare analyst review 2027<\/strong> finds no named brokerage coverage as of November 2026. Q2 FY27 revenue rose 17.3% to \u20b983.13 crore, EBITDA was \u20b917.95 crore with a 21.6% margin, and net profit rose to \u20b94.86 crore from \u20b91.21 crore. The stock traded at \u20b9239.15 on 19 November 2026, close to its 52-week high and about 51 times earnings, so the <strong>Amanta Healthcare share price target 2027<\/strong> question depends on whether profit growth can keep pace with the rally.<\/p>\n<\/div>\n<p>The <strong>Amanta Healthcare analyst review 2027<\/strong> covers a Gujarat-based maker of sterile liquid medicines, including IV fluids, small-volume injectables and eye and respiratory solutions packed in plastic containers. Readers searching for an <strong>Amanta Healthcare share price target 2027<\/strong> will not find any named <strong>brokerage<\/strong> figure, so results and valuation guide this review.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/amanta\/amanta-healthcare-ltd-share-price-today\">Amanta Healthcare<\/a> traded at \u20b9239.15 on 19 November 2026, about 3% below its 52-week high of \u20b9245.70 and roughly 2.6 times its low of \u20b992. This Amanta Healthcare analyst review 2027 explains the drivers behind the rally and the <strong>Amanta Healthcare stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=amanta-healthcare-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_Analysts_Say_in_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"What Analysts Say in the Amanta Healthcare Analyst Review 2027\">What Analysts Say in the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Q2_FY27_Results_in_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Amanta Healthcare Analyst Review 2027\">Q2 FY27 Results in the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#How_Amanta_Healthcare_Makes_Money\" title=\"How Amanta Healthcare Makes Money\">How Amanta Healthcare Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Growth_Triggers_in_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"Growth Triggers in the Amanta Healthcare Analyst Review 2027\">Growth Triggers in the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Key_Risks_in_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"Key Risks in the Amanta Healthcare Analyst Review 2027\">Key Risks in the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Amanta_Healthcare_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Amanta Healthcare Analyst Review 2027: Stock at a Glance\">Amanta Healthcare Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_to_Watch_After_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"What to Watch After the Amanta Healthcare Analyst Review 2027\">What to Watch After the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Final_Word_on_the_Amanta_Healthcare_Analyst_Review_2027\" title=\"Final Word on the Amanta Healthcare Analyst Review 2027\">Final Word on the Amanta Healthcare Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_does_the_Amanta_Healthcare_analyst_review_2027_show\" title=\"What does the Amanta Healthcare analyst review 2027 show?\">What does the Amanta Healthcare analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Is_there_an_Amanta_Healthcare_share_price_target_2027_from_brokerages\" title=\"Is there an Amanta Healthcare share price target 2027 from brokerages?\">Is there an Amanta Healthcare share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_does_Amanta_Healthcare_make\" title=\"What does Amanta Healthcare make?\">What does Amanta Healthcare make?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#How_will_the_solar_plant_help_Amanta_Healthcare\" title=\"How will the solar plant help Amanta Healthcare?\">How will the solar plant help Amanta Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#Is_Amanta_Healthcare_stock_expensive_based_on_the_Amanta_Healthcare_analyst_review_2027\" title=\"Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?\">Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_risks_does_the_Amanta_Healthcare_analyst_review_2027_highlight\" title=\"What risks does the Amanta Healthcare analyst review 2027 highlight?\">What risks does the Amanta Healthcare analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/amanta-healthcare-analyst-review\/#What_should_investors_track_after_the_Amanta_Healthcare_analyst_review_2027\" title=\"What should investors track after the Amanta Healthcare analyst review 2027?\">What should investors track after the Amanta Healthcare analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No named <strong>brokerage<\/strong> report with a target price could be verified. Amanta listed on the exchanges in 2025, and small recently listed pharma companies often go without regular research coverage.<\/p>\n<p>Domestic institutions nonetheless hold about 12.2% of the company, and that stake rose over the past year. This Amanta Healthcare analyst review 2027 uses that institutional interest and the quarterly numbers as the main reference points.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>\u20b983.13 crore<\/td>\n<td>\u20b970.89 crore<\/td>\n<td>Up 17.3%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>\u20b917.95 crore<\/td>\n<td>Not compared<\/td>\n<td>Margin 21.6%<\/td>\n<\/tr>\n<tr>\n<td>Net profit<\/td>\n<td>\u20b94.86 crore<\/td>\n<td>\u20b91.21 crore<\/td>\n<td>Up about 302%<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 revenue<\/td>\n<td>\u20b9151.94 crore<\/td>\n<td>Not compared<\/td>\n<td>Growing<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 net profit<\/td>\n<td>\u20b98.17 crore<\/td>\n<td>\u20b94.71 crore<\/td>\n<td>Up about 73%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Revenue grew steadily and <strong>EBITDA margin<\/strong> was a healthy 21.6%. The sharp jump in quarterly profit partly reflects an exceptional item of about \u20b93 crore that affects the year-on-year comparison, so the first-half figure is a cleaner guide.<\/p>\n<p>First-half <strong>net profit<\/strong> rose about 73% to \u20b98.17 crore, with the June quarter at \u20b93.31 crore and the September quarter at \u20b94.86 crore. In this Amanta Healthcare analyst review 2027, that sequential rise is the more useful signal.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Amanta_Healthcare_Makes_Money\"><\/span><strong>How Amanta Healthcare Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Amanta makes sterile liquid medicines using blow-fill-seal technology, which forms, fills and seals plastic containers in one step to keep products sterile.<\/p>\n<ul>\n<li><strong>Large-volume IV fluids:<\/strong> saline, dextrose and other infusion solutions for hospitals.<\/li>\n<li><strong>Small-volume injectables:<\/strong> ampoules and vials for injectable drugs.<\/li>\n<li><strong>Eye and respiratory products:<\/strong> drops and nebuliser solutions in single-dose packs.<\/li>\n<li><strong>Exports and contract work:<\/strong> supplies to overseas markets and other pharma companies.<\/li>\n<\/ul>\n<p>Sterile liquids are a volume business where plant utilisation and power costs decide margins. Amanta has commissioned a 10.8 MW solar power plant that it expects to save about \u20b99 crore a year in electricity costs, a meaningful amount against quarterly <strong>EBITDA<\/strong> of about \u20b918 crore. That saving frames this Amanta Healthcare analyst review 2027, because lower power costs flow almost directly into profit.<\/p>\n<p>Demand for IV fluids is steady, since hospitals need them regardless of economic cycles, but pricing is competitive and some products fall under government price controls. Exports and newer specialty products such as respiratory solutions offer better margins. Pharma stocks tracked by the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index have mostly larger, branded businesses, while Amanta sits in the more commoditised but steady hospital supplies segment.<\/p>\n<p><strong>Debt to equity<\/strong> of about 0.89 is relatively high, which means interest costs take a meaningful share of operating profit. That is one reason net profit of \u20b94.86 crore is much smaller than <strong>EBITDA<\/strong> of \u20b917.95 crore, along with depreciation on the plant. Reducing debt from cash flow would widen the gap between <strong>EBITDA<\/strong> and profit in shareholders&#8217; favour.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Revenue growth:<\/strong> up 17.3% in <strong>Q2 FY27<\/strong>.<\/li>\n<li><strong>Solar savings:<\/strong> about \u20b99 crore a year from the 10.8 MW plant.<\/li>\n<li><strong>Healthy margins:<\/strong> <strong>EBITDA<\/strong> margin of 21.6%.<\/li>\n<li><strong>Institutional interest:<\/strong> DII holding up to 12.2%.<\/li>\n<li><strong>Specialty products:<\/strong> eye and respiratory lines support the Amanta Healthcare share price target 2027 case.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>Key Risks in the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Valuation:<\/strong> about 51 times trailing earnings after a sharp rally.<\/li>\n<li><strong>Debt:<\/strong> <strong>debt to equity<\/strong> of about 0.89.<\/li>\n<li><strong>Price controls:<\/strong> some IV fluids face government pricing caps.<\/li>\n<li><strong>Regulatory checks:<\/strong> sterile plants face strict quality inspections.<\/li>\n<li><strong>Small profit base:<\/strong> quarterly profit under \u20b95 crore, a key point in the Amanta Healthcare analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Amanta Healthcare With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Amanta_Healthcare_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Amanta Healthcare Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (19 Nov 2026)<\/td>\n<td>\u20b9239.15<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9245.70 \/ \u20b992.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>About \u20b9928 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>About 50.7<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>About 51.5<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>About 4.1<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>About 8.0%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.89<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b958.75<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 51 is in line with the industry level, but return on equity is only about 8%. In this Amanta Healthcare analyst review 2027, the stock is priced for strong future growth, which leaves little room for a weak quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>63.56%<\/td>\n<td>63.80%<\/td>\n<td>Up 0.24 points<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>1.00%<\/td>\n<td>0.07%<\/td>\n<td>Down 0.93 points<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>11.34%<\/td>\n<td>12.20%<\/td>\n<td>Up 0.86 points<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>24.10%<\/td>\n<td>23.93%<\/td>\n<td>Down 0.17 points<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Bhavesh Patel holds 16.31% and Vishal Patel 10.06%, and the <strong>promoter<\/strong> stake edged higher. Domestic institutions added while foreign investors almost exited, a mixed signal in the Amanta Healthcare analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>What to Watch After the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margins:<\/strong> EBITDA margin holding above 20%.<\/li>\n<li><strong>Solar benefit:<\/strong> lower power costs in coming quarters.<\/li>\n<li><strong>Debt:<\/strong> repayment and interest costs.<\/li>\n<li><strong>Product mix:<\/strong> growth in specialty and export lines.<\/li>\n<li><strong>Coverage:<\/strong> any named note on the Amanta Healthcare share price target 2027.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Amanta_Healthcare_Analyst_Review_2027\"><\/span><strong>Final Word on the Amanta Healthcare Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Amanta Healthcare analyst review 2027<\/strong> shows steady revenue growth, healthy margins and cost savings from solar power, set against high debt, a small profit base and a valuation that already prices in growth after a sharp rally.<\/p>\n<p>The <strong>Amanta Healthcare stock outlook 2027<\/strong> depends on margins, debt reduction and product mix. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Amanta_Healthcare_analyst_review_2027_show\"><\/span><strong>What does the Amanta Healthcare analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows steady growth with healthy margins. Q2 FY27 revenue rose 17.3% to \u20b983.13 crore and EBITDA was \u20b917.95 crore with a 21.6% margin. Net profit rose to \u20b94.86 crore from \u20b91.21 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Amanta_Healthcare_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Amanta Healthcare share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No named brokerage target could be verified as of November 2026. The stock traded at \u20b9239.15 on 19 November 2026, about 3% below its 52-week high of \u20b9245.70. Results are the main reference point.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Amanta_Healthcare_make\"><\/span><strong>What does Amanta Healthcare make?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Amanta makes sterile liquid medicines such as IV fluids, small-volume injectables and eye and respiratory solutions. It uses blow-fill-seal technology to fill plastic containers. It sells to hospitals, export markets and other pharma companies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_will_the_solar_plant_help_Amanta_Healthcare\"><\/span><strong>How will the solar plant help Amanta Healthcare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Amanta has a 10.8 MW solar power plant that it expects to save about \u20b99 crore a year in power costs. That is large against quarterly EBITDA of about \u20b918 crore. The savings flow almost directly into profit.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Amanta_Healthcare_stock_expensive_based_on_the_Amanta_Healthcare_analyst_review_2027\"><\/span><strong>Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades at about 51 times earnings, in line with the industry P\/E of about 51.5. Return on equity is only about 8% and price to book is about 4.1. The price assumes strong future growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Amanta_Healthcare_analyst_review_2027_highlight\"><\/span><strong>What risks does the Amanta Healthcare analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are a high valuation after a sharp rally and debt to equity of about 0.89. Some IV fluids face government price controls. Sterile plants also face strict quality inspections.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Amanta_Healthcare_analyst_review_2027\"><\/span><strong>What should investors track after the Amanta Healthcare analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether EBITDA margin stays above 20% and how much the solar plant cuts power costs. Watch debt reduction and interest costs. Growth in specialty and export products also matters.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Amanta Healthcare analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows steady growth with healthy margins. Q2 FY27 revenue rose 17.3% to \u20b983.13 crore and EBITDA was \u20b917.95 crore with a 21.6% margin. Net profit rose to \u20b94.86 crore from \u20b91.21 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Amanta Healthcare share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No named brokerage target could be verified as of November 2026. The stock traded at \u20b9239.15 on 19 November 2026, about 3% below its 52-week high of \u20b9245.70. Results are the main reference point.\"}},{\"@type\":\"Question\",\"name\":\"What does Amanta Healthcare make?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Amanta makes sterile liquid medicines such as IV fluids, small-volume injectables and eye and respiratory solutions. It uses blow-fill-seal technology to fill plastic containers. It sells to hospitals, export markets and other pharma companies.\"}},{\"@type\":\"Question\",\"name\":\"How will the solar plant help Amanta Healthcare?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Amanta has a 10.8 MW solar power plant that it expects to save about \u20b99 crore a year in power costs. That is large against quarterly EBITDA of about \u20b918 crore. The savings flow almost directly into profit.\"}},{\"@type\":\"Question\",\"name\":\"Is Amanta Healthcare stock expensive based on the Amanta Healthcare analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock trades at about 51 times earnings, in line with the industry P\/E of about 51.5. Return on equity is only about 8% and price to book is about 4.1. The price assumes strong future growth.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Amanta Healthcare analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are a high valuation after a sharp rally and debt to equity of about 0.89. Some IV fluids face government price controls. Sterile plants also face strict quality inspections.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Amanta Healthcare analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether EBITDA margin stays above 20% and how much the solar plant cuts power costs. Watch debt reduction and interest costs. Growth in specialty and export products also matters.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Amanta Healthcare grew Q2 FY27 revenue 17% to \u20b983.13 crore with EBITDA margin of 21.6%, and profit rose to \u20b94.86 crore from \u20b91.21 crore. With no brokerage coverage, we review the IV fluids and sterile injectables business, valuation, debt and risks for 2027.<\/p>\n","protected":false},"author":34,"featured_media":356004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,26602,4341,26603],"class_list":["post-356005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-amanta-healthcare","tag-analyst-review","tag-sterile-injectables-and-iv-fluids"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["356004"],"rank_math_title":["Amanta Healthcare Share Price Target 2027: Review"],"rank_math_description":["Amanta Healthcare analyst review 2027: Q2 FY27 revenue up 17% to \u20b983 crore, EBITDA margin 21.6%, profit \u20b94.86 crore, solar savings, valuation near 51x, risks."],"rank_math_focus_keyword":["Amanta Healthcare analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/amanta-healthcare-analyst-review-2027-profit-up-fourfold-as-the-stock-nears-its.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=356005"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356005\/revisions"}],"predecessor-version":[{"id":356006,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356005\/revisions\/356006"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/356004"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=356005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=356005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=356005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}